Despite this, no heparanase inhibitors have been approved for clinical use as they are limited by cost, production complexity, and off target effects such as anticoagulant activity and thrombocytopenia resulting from their structural similarity to heparin [29, 66, 67]. The gene discussed is HPSE; the disease is Thrombocytopenia.